
Ibis Therapeutics is revolutionizing drug discovery with its AI-driven Molecular Fingerprint™ Platform, which integrates polypharmacology, selectivity profiling, safety assessments, and drug repurposing. This innovative approach addresses the complexities of drug interactions, focusing on maximizing efficacy while minimizing toxicity. By evaluating interactions across a vast array of drug candidates and protein targets, Ibis positions itself as a leader in precision medicine, catering to all stages of drug development and discovery.

Ibis Therapeutics is revolutionizing drug discovery with its AI-driven Molecular Fingerprint™ Platform, which integrates polypharmacology, selectivity profiling, safety assessments, and drug repurposing. This innovative approach addresses the complexities of drug interactions, focusing on maximizing efficacy while minimizing toxicity. By evaluating interactions across a vast array of drug candidates and protein targets, Ibis positions itself as a leader in precision medicine, catering to all stages of drug development and discovery.
Founded: 2017
Headquarters: Tampa, Florida
Core tech: AI-driven Molecular Fingerprint™ platform for proteome-wide drug–target interaction profiling
Notable partners/investors: XLerateHealth; strategic collaboration and investment from Mayo Clinic
Company size (reported): 1-10 employees
Drug discovery and safety/selectivity profiling to address complex drug–target interaction landscapes.
2017
Biotechnology
Selected for XLerateHealth 2020 accelerator cohort.
Mayo Clinic entered a strategic collaboration and was reported to invest to help expand the platform.
“Presence of accelerator selection by XLerateHealth and a strategic collaboration/investment from Mayo Clinic indicates early-stage external backing and strategic partner investment.”